Semaglutide vs Tirzepatide: What the 2026 Data Actually Shows

The First Real Head-to-Head

For years, comparing these two drugs meant stitching together results from separate trials with different patient populations, different protocols, and different endpoints — then arguing about what the numbers meant. That changed in May 2025 when the SURMOUNT-5 trial published its results: the first large, randomized, head-to-head comparison of tirzepatide and semaglutide for weight loss.

The headline finding: tirzepatide wins on weight loss. But the story is more complicated than that — and more useful — if you look at the full picture.

This article covers the mechanism differences, the trial data (with actual numbers), the side effect profiles, the costs in 2026, the insurance reality, and an honest verdict on which drug fits which situation. We're not here to tell you tirzepatide always wins. In some cases, semaglutide is the better pick.

How They Work: GLP-1 vs Dual Agonist

Both drugs belong to the GLP-1 receptor agonist class. But they're not identical.

Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss) is a single GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone, which slows gastric emptying, reduces appetite, and stimulates insulin release in response to food. It's administered as a once-weekly subcutaneous injection (or, as of January 2026, an oral daily pill in the form of Wegovy HD).

Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss) is a dual GIP/GLP-1 receptor agonist — what researchers call a "twincretin." It activates both the GLP-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway simultaneously. This dual activation appears to be what drives tirzepatide's greater average weight loss. Also a once-weekly injection.

The mechanism difference matters because it partially explains the weight loss gap — and why cardiovascular outcomes may differ between the two, which we'll get to. For more on how GLP-1 mechanisms work in depth, see our GLP-1 Peptides: Complete Weight Loss Guide.

The SURMOUNT-5 Head-to-Head Trial: What It Actually Found

SURMOUNT-5 was published in The New England Journal of Medicine in May 2025. It was a Phase 3b, multicenter, open-label, randomized trial comparing tirzepatide and semaglutide directly in 751 adults with obesity but without type 2 diabetes, over 72 weeks. Participants were randomized to the maximum tolerated dose: tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), each once weekly.

Primary results at 72 weeks:

Outcome	Tirzepatide	Semaglutide
Mean body weight reduction	20.2%	13.7%
Mean weight lost (absolute)	~50.3 lbs (22.8 kg)	~33.1 lbs (15.0 kg)
Achieved ≥15% weight loss	64.6%	40.1%
Achieved ≥20% weight loss	48.4%	27.3%
Achieved ≥25% weight loss	31.6%	16.1%
Achieved ≥30% weight loss	19.7%	6.9%
Waist circumference reduction	18.4 cm (7.2 in)	13.0 cm (5.1 in)

Tirzepatide was statistically superior on the primary endpoint and all five key secondary endpoints. The 6.5-percentage-point gap in mean weight loss translates to roughly 47% greater relative weight reduction.

One important context note: SURMOUNT-5 was funded by Eli Lilly, the manufacturer of tirzepatide. This is standard for Phase 3 trials — NEJM's peer review is substantive, and the result is consistent with independent meta-analyses. But it's the right disclosure to note.

For context, the individual trial programs:

• SURMOUNT-1 (tirzepatide 15 mg alone vs placebo): 22.5% mean weight loss at 72 weeks
• STEP-1 (semaglutide 2.4 mg vs placebo): ~15% mean weight loss at 68 weeks

These separate trial results are directionally consistent with the SURMOUNT-5 head-to-head, though cross-trial comparisons are less reliable than direct comparison.

Side Effects: Where Each Drug Wins and Loses

Both drugs share the same class of common side effects: nausea, diarrhea, vomiting, and constipation. These are largely predictable, occur mostly during the dose-escalation phase, and are mild to moderate in most patients.

The SURMOUNT-5 data provides the cleanest apples-to-apples comparison:

Side Effect Metric	Tirzepatide	Semaglutide
Stopped due to GI adverse events	2.7%	5.6%
Injection site reactions	8.6%	0.3%
Nausea (any)	Similar to semaglutide	Similar to tirzepatide
Gallbladder disease	Class effect	Class effect

The GI discontinuation difference is meaningful. If you tolerate GLP-1s poorly, tirzepatide may be the more manageable option — at least in this trial. The injection site reaction difference goes the other way: semaglutide is clearly better there.

Other considerations: both drugs are associated with gallbladder disease at higher rates than placebo — a known class effect. Lean mass loss has emerged as a concern with both drugs, particularly in women and older adults. Resistance exercise during treatment is recommended by most obesity medicine physicians. Neither drug is approved during pregnancy.

The bottom line on side effects: tirzepatide shows lower GI-driven discontinuation rates; semaglutide shows fewer injection site reactions. Neither is obviously "gentler" across the board.

The Cardiovascular Case for Semaglutide

This is where the conversation becomes important for anyone comparing these drugs based on weight loss data alone.

The SELECT trial (published November 2023) enrolled over 17,000 adults with established cardiovascular disease, overweight or obesity, and no diabetes. Over an average 40-month follow-up, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE — cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 20% compared to placebo (HR 0.80; 95% CI 0.72–0.90; p<0.001). The event rate was 6.5% with semaglutide versus 8.0% with placebo — a 1.5 percentage-point absolute risk reduction. Notably, this cardiovascular benefit was found to be independent of the degree of weight loss.

In March 2026, NICE (the UK health technology authority) recommended Wegovy specifically for cardiovascular risk reduction in adults with established CVD and obesity — the first GLP-1 agent to receive this recommendation.

The STEER real-world study (presented at ESC Congress 2025) compared cardiovascular outcomes between Wegovy users and tirzepatide users in people with obesity and established CVD. In patients who stayed on treatment without gaps, Wegovy showed a 57% greater reduction in the risk of heart attack, stroke, or cardiovascular death compared to tirzepatide. Across all treated patients regardless of gaps, the reduction was 29%.

These are real-world observational data, not randomized trials, and the follow-up periods were short (3.8–8.6 months). Interpret them as directional, not definitive. But the SELECT RCT result for semaglutide is Level 1 evidence — and tirzepatide has no comparable randomized cardiovascular outcomes trial completed yet.

The verdict on cardiovascular history: If a patient has established cardiovascular disease, semaglutide is currently the evidence-backed choice. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Until that data publishes, clinicians managing patients with both obesity and CVD have one drug with proven cardioprotection — and it isn't tirzepatide.

Cost in 2026: How They Compare

Both drugs have nearly identical list prices and self-pay structures. Neither is meaningfully cheaper than the other at full retail. For detailed cost breakdowns including compounded versions and telehealth options, see our Peptide Therapy Cost guide.

Option	Wegovy (semaglutide)	Zepbound (tirzepatide)
List price	~$1,350/month	~$1,000–$1,086/month
Self-pay via manufacturer program	$149–$399/month (NovoCare)	~$299–$549/month (LillyDirect)
With commercial insurance + savings card	As low as $25/month	As low as $25/month
Compounded (telehealth)	$99–$299/month	$99–$350/month

Insurance coverage reality in 2026:

• Commercial insurance: Coverage for both drugs is inconsistent — depends entirely on your plan and diagnosis
• Medicare: Does not cover either drug for weight loss; Medicare Part D now covers Wegovy specifically for cardiovascular risk reduction
• Medicaid: Only 13 states cover GLP-1s for weight loss
• Formulary edge: CVS Caremark currently prefers Wegovy over Zepbound on their formulary, which can mean better commercial coverage for semaglutide depending on your PBM

The insurance picture is where semaglutide has a practical advantage for many patients: broader formulary placement, longer on-market history, and the new cardiovascular indication expanding Medicare access in select patients. If insurance coverage is the deciding factor, semaglutide often wins by default.

Dosing: What to Expect From Each

Both drugs are once-weekly subcutaneous injections that require a titration period to reach maintenance doses.

Drug	Starting Dose	Maintenance Dose	Weeks to Maintenance
Semaglutide (Wegovy)	0.25 mg/week	2.4 mg/week	~17 weeks
Tirzepatide (Zepbound)	2.5 mg/week	10–15 mg/week	~20–24 weeks

Both titration schedules are comparable in length. Neither drug delivers maximum effect overnight — the weight loss results from SURMOUNT-5 accumulated over 72 weeks, not 16.

As of January 2026, oral Wegovy HD (once-daily 7.2 mg tablet) became available — the only oral option in this class at a comparable maintenance dose.

Who Each Drug Fits Best

Tirzepatide is likely the better pick if:

• Your primary goal is maximum weight loss
• You've tried semaglutide and didn't achieve adequate response or couldn't tolerate the GI side effects
• You don't have established cardiovascular disease that makes the SELECT data directly applicable
• Your insurance covers Zepbound or you're paying cash

Semaglutide is likely the better pick if:

• You have a history of heart attack, stroke, or established cardiovascular disease — the SELECT trial applies to you
• Your insurance formulary favors Wegovy (ask your pharmacy benefit manager)
• You're on Medicare with a cardiovascular indication
• You prefer the oral pill option (Wegovy HD, launched January 2026)
• You're earlier in the GLP-1 class and want the drug with a longer safety track record

The honest bottom line: Tirzepatide produces more weight loss on average. Semaglutide has proven cardiovascular benefits that tirzepatide doesn't yet have evidence for. These are not trivial differences — and neither drug is universally "better." The right answer depends on your health profile, your goals, and what your insurance will cover.

For the full breakdown of how GLP-1s work, dosing protocols, and sourcing considerations, see our GLP-1 Peptides Complete Guide. For a cost breakdown by route, see the Peptide Therapy Cost guide.

Frequently Asked Questions

Is tirzepatide stronger than semaglutide for weight loss?

Yes, in head-to-head data. The SURMOUNT-5 trial (NEJM, May 2025) showed tirzepatide produced 20.2% mean weight loss versus 13.7% with semaglutide over 72 weeks in adults with obesity and no diabetes. Tirzepatide's dual GIP/GLP-1 mechanism appears to drive greater average weight reduction than semaglutide's single GLP-1 mechanism. That said, individual response varies — some patients lose more weight on semaglutide than on tirzepatide.

Which has fewer side effects — semaglutide or tirzepatide?

Neither is clearly "easier" overall, but the pattern differs. In SURMOUNT-5, more semaglutide patients stopped treatment due to gastrointestinal side effects (5.6% vs 2.7%). But tirzepatide caused more injection site reactions (8.6% vs 0.3%). Both drugs cause nausea, diarrhea, vomiting, and constipation most commonly during dose escalation. The severity is usually mild to moderate and improves over time.

Can you switch from semaglutide to tirzepatide, or vice versa?

Yes — physicians do this routinely. A common reason to switch from semaglutide to tirzepatide is inadequate weight loss response. A common reason to consider switching the other direction: if a patient has cardiovascular disease and the SELECT trial data is clinically relevant, or if insurance only covers semaglutide. There's no standardized washout period required between the two drugs, but dosing restarts at the lowest titration dose when switching.

Does semaglutide reduce heart attack risk?

Yes. The SELECT trial showed semaglutide 2.4 mg reduced the risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20% in adults with established cardiovascular disease and obesity but no diabetes — independent of weight loss. In March 2026, NICE in the UK recommended Wegovy specifically for cardiovascular risk reduction on the basis of SELECT data. This cardiovascular indication does not currently exist for tirzepatide.

Which GLP-1 does insurance cover better in 2026?

It depends heavily on your insurer and your plan. Wegovy (semaglutide) generally has better commercial formulary placement — CVS Caremark, for example, currently prefers Wegovy over Zepbound. For Medicare patients with cardiovascular disease, Wegovy's new cardiovascular indication may create coverage pathways that Zepbound doesn't have. Medicaid coverage for either drug for weight loss is limited to about 13 states. Check directly with your insurance before assuming either drug is covered.

How long does it take to see results on tirzepatide vs semaglutide?

Both drugs take time. In SURMOUNT-5, the 20.2% (tirzepatide) and 13.7% (semaglutide) results were measured at 72 weeks. Neither drug produces maximum effect in the first month — the titration schedule alone takes 20–24 weeks for tirzepatide and 17 weeks for semaglutide before reaching the full maintenance dose. Expect meaningful results to emerge at 12–16 weeks, with the full picture clearer at 6+ months.